298 related articles for article (PubMed ID: 26351383)
41. Fecal Calprotectin in Assessing Endoscopic and Histological Remission in Patients with Ulcerative Colitis.
Mak WY; Buisson A; Andersen MJ; Lei D; Pekow J; Cohen RD; Kahn SA; Pereira B; Rubin DT
Dig Dis Sci; 2018 May; 63(5):1294-1301. PubMed ID: 29468374
[TBL] [Abstract][Full Text] [Related]
42. The role of calprotectin in predicting endoscopic post-surgical recurrence in asymptomatic Crohn's disease: a comparison with ultrasound.
Orlando A; Modesto I; Castiglione F; Scala L; Scimeca D; Rispo A; Teresi S; Mocciaro F; Criscuoli V; Marrone C; Platania P; De Falco T; Maisano S; Nicoli N; Cottone M
Eur Rev Med Pharmacol Sci; 2006; 10(1):17-22. PubMed ID: 16494106
[TBL] [Abstract][Full Text] [Related]
43. Level of Fecal Calprotectin Correlates With Severity of Small Bowel Crohn's Disease, Measured by Balloon-assisted Enteroscopy and Computed Tomography Enterography.
Arai T; Takeuchi K; Miyamura M; Ishikawa R; Yamada A; Katsumata M; Igarashi Y; Suzuki Y
Clin Gastroenterol Hepatol; 2017 Jan; 15(1):56-62. PubMed ID: 27565523
[TBL] [Abstract][Full Text] [Related]
44. Association of Biomarker Cutoffs and Endoscopic Outcomes in Crohn's Disease: A Post Hoc Analysis From the CALM Study.
Reinisch W; Panaccione R; Bossuyt P; Baert F; Armuzzi A; Hébuterne X; Travis S; Danese S; Sandborn WJ; Schreiber S; Berg S; Zhou Q; Kligys K; Neimark E; Suleiman AA; D'Haens G; Colombel JF
Inflamm Bowel Dis; 2020 Sep; 26(10):1562-1571. PubMed ID: 32105310
[TBL] [Abstract][Full Text] [Related]
45. Does fecal calprotectin predict relapse in patients with Crohn's disease and ulcerative colitis?
García-Sánchez V; Iglesias-Flores E; González R; Gisbert JP; Gallardo-Valverde JM; González-Galilea A; Naranjo-Rodríguez A; de Dios-Vega JF; Muntané J; Gómez-Camacho F
J Crohns Colitis; 2010 Jun; 4(2):144-52. PubMed ID: 21122498
[TBL] [Abstract][Full Text] [Related]
46. Elevated Faecal Calprotectin Levels are a Reliable Non-Invasive Screening Tool for Small Bowel Crohn's Disease in Patients Undergoing Capsule Endoscopy.
Yousuf H; Aleem U; Egan R; Maheshwari P; Mohamad J; McNamara D
Dig Dis; 2018; 36(3):202-208. PubMed ID: 29466790
[TBL] [Abstract][Full Text] [Related]
47. Fecal Calprotectin in Ileal Crohn's Disease: Relationship with Magnetic Resonance Enterography and a Pathology Score.
Cerrillo E; Beltrán B; Pous S; Echarri A; Gallego JC; Iborra M; Pamies J; Nos P
Inflamm Bowel Dis; 2015 Jul; 21(7):1572-9. PubMed ID: 26052967
[TBL] [Abstract][Full Text] [Related]
48. Rapid Fecal Calprotectin Test and Symptom Index in Monitoring the Disease Activity in Colonic Inflammatory Bowel Disease.
Puolanne AM; Kolho KL; Alfthan H; Ristimäki A; Mustonen H; Färkkilä M
Dig Dis Sci; 2017 Nov; 62(11):3123-3130. PubMed ID: 28948412
[TBL] [Abstract][Full Text] [Related]
49. Associations Among Mucosal and Transmural Healing and Fecal Level of Calprotectin in Children With Crohn's Disease.
Weinstein-Nakar I; Focht G; Church P; Walters TD; Abitbol G; Anupindi S; Berteloot L; Hulst JM; Ruemmele F; Lemberg DA; Leach ST; Cytter R; Greer ML; Griffiths AM; Turner D;
Clin Gastroenterol Hepatol; 2018 Jul; 16(7):1089-1097.e4. PubMed ID: 29501599
[TBL] [Abstract][Full Text] [Related]
50. Accurate cut-offs for predicting endoscopic activity and mucosal healing in Crohn's disease with fecal calprotectin.
Vázquez Morón JM; Pallarés Manrique H; Machancoses FH; Ramos Lora M; Ruiz Frutos C
Rev Esp Enferm Dig; 2017 Feb; 109(2):130-136. PubMed ID: 28071062
[TBL] [Abstract][Full Text] [Related]
51. Development and Validation of a Test to Monitor Endoscopic Activity in Patients With Crohn's Disease Based on Serum Levels of Proteins.
D'Haens G; Kelly O; Battat R; Silverberg MS; Laharie D; Louis E; Savarino E; Bodini G; Yarur A; Boland BS; Afif W; Li XJ; Hale M; Ho J; Kondragunta V; Huang B; Kuy C; Okada L; Hester KD; Bray KR; Mimms L; Jain A; Singh S; Collins A; Valasek MA; Sandborn WJ; Vermeire S; Dulai PS
Gastroenterology; 2020 Feb; 158(3):515-526.e10. PubMed ID: 31711925
[TBL] [Abstract][Full Text] [Related]
52. Fecal calprotectin as a biomarker of inflammatory lesions of the small bowel seen by videocapsule endoscopy.
Egea-Valenzuela J; Alberca-de-Las-Parras F; Carballo-Álvarez F
Rev Esp Enferm Dig; 2015 Apr; 107(4):211-4. PubMed ID: 25824919
[TBL] [Abstract][Full Text] [Related]
53. Correlation between fecal calprotectin and inflammation in the surgical specimen of Crohn's disease.
Pous-Serrano S; Frasson M; Cerrillo E; Beltrán B; Iborra M; Hervás D; García-Granero E; Nos P
J Surg Res; 2017 Jun; 213():290-297. PubMed ID: 28601328
[TBL] [Abstract][Full Text] [Related]
54. Biomarker-Based Models Outperform Patient-Reported Scores in Predicting Endoscopic Inflammatory Disease Activity.
Morris MW; Stewart SA; Heisler C; Sandborn WJ; Loftus EV; Zello GA; Fowler SA; Jones JL
Inflamm Bowel Dis; 2018 Jan; 24(2):277-285. PubMed ID: 29361090
[TBL] [Abstract][Full Text] [Related]
55. Profile of Consecutive Fecal Calprotectin Levels in the Perioperative Period and Its Predictive Capacity for Early Endoscopic Recurrence in Crohn's Disease.
Liu R; Guo Z; Cao L; Wang Z; Gong J; Li Y; Zhu W
Dis Colon Rectum; 2019 Mar; 62(3):318-326. PubMed ID: 30451756
[TBL] [Abstract][Full Text] [Related]
56. Validation of endoscopic activity scores in patients with Crohn's disease based on a post hoc analysis of data from SONIC.
Ferrante M; Colombel JF; Sandborn WJ; Reinisch W; Mantzaris GJ; Kornbluth A; Rachmilewitz D; Lichtiger S; D'Haens GR; van der Woude CJ; Danese S; Diamond RH; Oortwijn AF; Tang KL; Miller M; Cornillie F; Rutgeerts PJ;
Gastroenterology; 2013 Nov; 145(5):978-986.e5. PubMed ID: 23954314
[TBL] [Abstract][Full Text] [Related]
57. Noninvasive Fecal Immunochemical Testing and Fecal Calprotectin Predict Mucosal Healing in Inflammatory Bowel Disease: A Prospective Cohort Study.
Ma C; Lumb R; Walker EV; Foshaug RR; Dang TT; Verma S; Huang VW; Kroeker KI; Wong K; Dieleman LA; Fedorak RN; Halloran BP
Inflamm Bowel Dis; 2017 Sep; 23(9):1643-1649. PubMed ID: 28644184
[TBL] [Abstract][Full Text] [Related]
58. Faecal Myeloperoxidase as a Biomarker of Endoscopic Activity in Inflammatory Bowel Disease.
Swaminathan A; Borichevsky GM; Edwards TS; Hirschfeld E; Mules TC; Frampton CMA; Day AS; Hampton MB; Kettle AJ; Gearry RB
J Crohns Colitis; 2022 Dec; 16(12):1862-1873. PubMed ID: 35803583
[TBL] [Abstract][Full Text] [Related]
59. High Percentage of IBD Patients with Indefinite Fecal Calprotectin Levels: Additional Value of a Combination Score.
Bodelier AG; Jonkers D; van den Heuvel T; de Boer E; Hameeteman W; Masclee AA; Pierik MJ
Dig Dis Sci; 2017 Feb; 62(2):465-472. PubMed ID: 27933473
[TBL] [Abstract][Full Text] [Related]
60. The Utility of Fecal Calprotectin in the Real-World Clinical Care of Patients with Inflammatory Bowel Disease.
Abej E; El-Matary W; Singh H; Bernstein CN
Can J Gastroenterol Hepatol; 2016; 2016():2483261. PubMed ID: 27774443
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
